Luke Sheridan-Reins explores a recent paper on the contribution of cannabis use to variation in the incidence of psychotic disorder across Europe.[read the full story...]
As we prepare for our Cannabis #MHQT event on Wed 26 Sep, Luke Sheridan Rains dissects a narrative review that asks: Is cannabis treatment for anxiety, mood, and related disorders ready for prime time?
His answer is that current evidence does not support the use of medical cannabis for mental illnesses such as anxiety or depression.[read the full story...]
Luke Sheridan Rains publishes his debut blog on a recent multicentre RCT of Cannabidiol (CBD) as an adjunctive therapy for people with schizophrenia, which suggests that CBD had a beneficial, but modest impact on positive psychotic symptoms and severity of illness when used alongside existing antipsychotics.[read the full story...]